Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
Paul A DiSilvestroSusana BanerjeeNicoletta ColomboGiovanni ScambiaByoung-Gie KimAna OakninMichael L FriedlanderAlla LisyanskayaAnne FloquetAlexandra LearyGabe S SonkeCharlie GourleyAmit M OzaAntonio Gonzáles MartinCarol AghajanianWilliam H BradleyCara A MathewsJoyce F LiuJohn McNamaraElizabeth S LoweMei-Lin Ah-SeeKathleen M Moorenull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Results indicate a clinically meaningful, albeit not statistically significant according to prespecified criteria, improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for cure may also be enhanced. No new safety signals were observed during long-term follow-up.